[시장보고서]무균 주사제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2031년)

무균 주사제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2031년)

Sterile Injectable Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

상품코드 : 1442901

리서치사 : Transparency Market Research

발행일 : 2024년 01월

페이지 정보 : 영문 222 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,795

￦ 8,603,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795

￦ 13,057,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795

￦ 17,512,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

샘플 요청 목록에 추가

무균 주사제 시장 - 보고서 범위

세계 무균 주사제 시장에 대한 TMR의 보고서는 과거와 현재의 성장 추세와 2023년부터 2031년까지의 예측 기간 동안 시장 지표에 대한 귀중한 인사이트를 얻을 수 있는 기회를 연구하고 있습니다. 이 보고서는 세계 무균 주사제 시장의 수익을 제공합니다. 2023년을 기준 연도, 2031년을 예측 연도로 간주하여 2017년부터 2031년까지의 시장을 분석합니다. 이 보고서는 또한 2023년부터 2031년까지 세계 무균 주사제 시장의 복합 연간 성장률(CAGR %)을 제공합니다.

이 보고서는 광범위한 조사를 통해 작성되었습니다. 1차 조사에서는 주요 오피니언 리더, 업계 리더, 오피니언 메이커를 대상으로 애널리스트가 인터뷰하는 방식으로 대부분의 조사 활동이 이루어졌습니다. 2차 조사에는 무균 주사제 시장을 이해하기 위해 주요 기업의 제품 문헌, 연례 보고서, 보도 자료 및 관련 문서에 대한 참조가 포함됩니다.

이 보고서는 세계 무균 주사제 시장의 경쟁 구도를 심층적으로 분석합니다. 세계 무균 주사제 시장에서 활동하는 주요 기업들이 확인되었으며, 이들 각각은 다양한 속성 측면에서 프로파일링되었습니다. 회사 개요, 재무 상태, 최근 동향 및 SWOT는 이 보고서에 설명된 세계 무균 주사제 시장의 기업 속성입니다.

소개
- 주요 조사 결과
시장 금액 예측 : 유형별, 2017-2031년
- 저분자
- 고분자
시장 매력 : 유형별
시장 금액 예측 : 약제 클래스별, 2017-2031년
- 단클론항체(Mab)
- 사이토카인
- 인슐린
- 펩타이드 호르몬
- 백신
- 면역글로불린
- 혈액인자
- 펩타이드 항생제
- 기타
시장 매력도 : 약제 클래스별
시장 금액 예측 : 지표별, 2017-2031년
- 심장병과 대사질환
- 신경내과
- 종양학
- 자가면역
- 소화기과
- 혈액학
- 통증
- 감염증
- 기타
시장 매력 : 적응증별
시장 금액 예측 : 유통 채널별, 2017-2031년
- 병원 약국
- 소매 약국
- E-Commerce
시장 매력 : 유통 채널별
시장 금액 예측 : 국가/하위 지역별, 2017-2031년
- GCC 국가
- 남아프리카공화국
- 기타 중동 및 아프리카
시장 매력 분석
- 유형별
- 약제 클래스별
- 적응증별
- 유통 채널별
- 국가/하위 지역별

제16장 경쟁 상황

시장 기업 - 경쟁 매트릭스(기업 계층 및 규모별)
시장 점유율 분석 : 기업별(2022년)
기업 개요
- Baxter International
- Sanofi SA
- Pfizer, Inc.
- GlaxoSmithKline Plc.
- AstraZeneca
- Merck &Co., Inc.
- Novartis AG
- Johnson & Johnson Services, Inc.
- Novo Nordisk A/S
- Gilead Sciences, Inc.

KSM

영문 목차

영문목차

Sterile Injectable Drugs Market - Scope of Report

TMR's report on the global dementia associated with Alzheimer's disease market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global dementia associated with Alzheimer's disease market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global dementia associated with Alzheimer's disease market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the dementia associated with Alzheimer's disease market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global dementia associated with Alzheimer's disease market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global dementia associated with Alzheimer's disease market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global dementia associated with Alzheimer's disease market.

The report delves into the competitive landscape of the global dementia associated with Alzheimer's disease market. Key players operating in the global dementia associated with Alzheimer's disease market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global dementia associated with Alzheimer's disease market profiled in this report.

Key Questions Answered in Global dementia associated with Alzheimer's disease Market Report:

What is the sales/revenue generated by dementia associated with Alzheimer's disease across all regions during the forecast period?
What are the opportunities in the global dementia associated with Alzheimer's disease market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Sterile Injectable Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global dementia associated with Alzheimer's disease market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global dementia associated with Alzheimer's disease market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global dementia associated with Alzheimer's disease market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Sterile Injectable Drugs Market

4. Market Overview

4.1. Introduction
- 4.1.1. Type Definition
- 4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Sterile Injectable Drugs Market Analysis and Forecast, 2017-2031

5. Key Insights

5.1. Pipeline Analysis
5.2. Key Type/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Sterile Injectable Drugs Market Analysis and Forecast, by Type

6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017-2031
- 6.3.1. Small Molecule
- 6.3.2. Large Molecule
6.4. Market Attractiveness, by Type

7. Global Sterile Injectable Drugs Market Analysis and Forecast, by Drug Class

7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Drug Class, 2017-2031
- 7.3.1. Monoclonal Antibodies (Mabs)
- 7.3.2. Cytokines
- 7.3.3. Insulin
- 7.3.4. Peptide Hormones
- 7.3.5. Vaccine
- 7.3.6. Immunoglobulins
- 7.3.7. Blood Factors
- 7.3.8. Peptide Antibiotics
- 7.3.9. Others
7.4. Market Attractiveness, by Drug Class

8. Global Sterile Injectable Drugs Market Analysis and Forecast, by Indication

8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Indication, 2017-2031
- 8.3.1. Cardiology & Metabolic Disorders
- 8.3.2. Neurology
- 8.3.3. Oncology
- 8.3.4. Autoimmune
- 8.3.5. Gastroenterology
- 8.3.6. Hematology
- 8.3.7. Pain
- 8.3.8. Infectious Disease
- 8.3.9. Others
8.4. Market Attractiveness, by Indication

9. Global Sterile Injectable Drugs Market Analysis and Forecast, by Distribution Channel

9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 9.3.1. Hospital Pharmacy
- 9.3.2. Retail Pharmacy
- 9.3.3. E-commerce
9.4. Market Attractiveness, by Distribution Channel

10. Global Sterile Injectable Drugs Market Analysis and Forecast, by Region

10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region

11. North America Sterile Injectable Drugs Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017-2031
- 11.2.1. Small Molecule
- 11.2.2. Large Molecule
11.3. Market Attractiveness, by Type
11.4. Market Value Forecast, by Drug Class, 2017-2031
- 11.4.1. Monoclonal Antibodies (Mabs)
- 11.4.2. Cytokines
- 11.4.3. Insulin
- 11.4.4. Peptide Hormones
- 11.4.5. Vaccine
- 11.4.6. Immunoglobulins
- 11.4.7. Blood Factors
- 11.4.8. Peptide Antibiotics
- 11.4.9. Others
11.5. Market Attractiveness, by Drug Class
11.6. Market Value Forecast, by Indication, 2017-2031
- 11.6.1. Cardiology & Metabolic Disorders
- 11.6.2. Neurology
- 11.6.3. Oncology
- 11.6.4. Autoimmune
- 11.6.5. Gastroenterology
- 11.6.6. Hematology
- 11.6.7. Pain
- 11.6.8. Infectious Disease
- 11.6.9. Others
11.7. Market Attractiveness, by Indication
11.8. Market Value Forecast, by Distribution Channel, 2017-2031
- 11.8.1. Hospital Pharmacy
- 11.8.2. Retail Pharmacy
- 11.8.3. E-commerce
11.9. Market Attractiveness, by Distribution Channel
11.10. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.10.1. U.S.
- 11.10.2. Canada
11.11. Market Attractiveness Analysis
- 11.11.1. By Type
- 11.11.2. By Drug Class
- 11.11.3. By Indication
- 11.11.4. By Distribution Channel
- 11.11.5. By Country

12. Europe Sterile Injectable Drugs Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017-2031
- 12.2.1. Small Molecule
- 12.2.2. Large Molecule
12.3. Market Attractiveness, by Type
12.4. Market Value Forecast, by Drug Class, 2017-2031
- 12.4.1. Monoclonal Antibodies (Mabs)
- 12.4.2. Cytokines
- 12.4.3. Insulin
- 12.4.4. Peptide Hormones
- 12.4.5. Vaccine
- 12.4.6. Immunoglobulins
- 12.4.7. Blood Factors
- 12.4.8. Peptide Antibiotics
- 12.4.9. Others
12.5. Market Attractiveness, by Drug Class
12.6. Market Value Forecast, by Indication, 2017-2031
- 12.6.1. Cardiology & Metabolic Disorders
- 12.6.2. Neurology
- 12.6.3. Oncology
- 12.6.4. Autoimmune
- 12.6.5. Gastroenterology
- 12.6.6. Hematology
- 12.6.7. Pain
- 12.6.8. Infectious Disease
- 12.6.9. Others
12.7. Market Attractiveness, by Indication
12.8. Market Value Forecast, by Distribution Channel, 2017-2031
- 12.8.1. Hospital Pharmacy
- 12.8.2. Retail Pharmacy
- 12.8.3. E-commerce
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.10.1. Germany
- 12.10.2. U.K.
- 12.10.3. France
- 12.10.4. Italy
- 12.10.5. Spain
- 12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
- 12.11.1. By Type
- 12.11.2. By Drug Class
- 12.11.3. By Indication
- 12.11.4. By Distribution Channel
- 12.11.5. By Country/Sub-region

13. Asia Pacific Sterile Injectable Drugs Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017-2031
- 13.2.1. Small Molecule
- 13.2.2. Large Molecule
13.3. Market Attractiveness, by Type
13.4. Market Value Forecast, by Drug Class, 2017-2031
- 13.4.1. Monoclonal Antibodies (Mabs)
- 13.4.2. Cytokines
- 13.4.3. Insulin
- 13.4.4. Peptide Hormones
- 13.4.5. Vaccine
- 13.4.6. Immunoglobulins
- 13.4.7. Blood Factors
- 13.4.8. Peptide Antibiotics
- 13.4.9. Others
13.5. Market Attractiveness, by Drug Class
13.6. Market Value Forecast, by Indication, 2017-2031
- 13.6.1. Cardiology & Metabolic Disorders
- 13.6.2. Neurology
- 13.6.3. Oncology
- 13.6.4. Autoimmune
- 13.6.5. Gastroenterology
- 13.6.6. Hematology
- 13.6.7. Pain
- 13.6.8. Infectious Disease
- 13.6.9. Others
13.7. Market Attractiveness, by Indication
13.8. Market Value Forecast, by Distribution Channel, 2017-2031
- 13.8.1. Hospital Pharmacy
- 13.8.2. Retail Pharmacy
- 13.8.3. E-commerce
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.10.1. China
- 13.10.2. Japan
- 13.10.3. India
- 13.10.4. Australia & New Zealand
- 13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
- 13.11.1. By Type
- 13.11.2. By Drug Class
- 13.11.3. By Indication
- 13.11.4. By Distribution Channel
- 13.11.5. By Country/Sub-region

14. Latin America Sterile Injectable Drugs Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017-2031
- 14.2.1. Small Molecule
- 14.2.2. Large Molecule
14.3. Market Attractiveness, by Type
14.4. Market Value Forecast, by Drug Class, 2017-2031
- 14.4.1. Monoclonal Antibodies (Mabs)
- 14.4.2. Cytokines
- 14.4.3. Insulin
- 14.4.4. Peptide Hormones
- 14.4.5. Vaccine
- 14.4.6. Immunoglobulins
- 14.4.7. Blood Factors
- 14.4.8. Peptide Antibiotics
- 14.4.9. Others
14.5. Market Attractiveness, by Drug Class
14.6. Market Value Forecast, by Indication, 2017-2031
- 14.6.1. Cardiology & Metabolic Disorders
- 14.6.2. Neurology
- 14.6.3. Oncology
- 14.6.4. Autoimmune
- 14.6.5. Gastroenterology
- 14.6.6. Hematology
- 14.6.7. Pain
- 14.6.8. Infectious Disease
- 14.6.9. Others
14.7. Market Attractiveness, by Indication
14.8. Market Value Forecast, by Distribution Channel, 2017-2031
- 14.8.1. Hospital Pharmacy
- 14.8.2. Retail Pharmacy
- 14.8.3. E-commerce
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.10.1. Brazil
- 14.10.2. Mexico
- 14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
- 14.11.1. By Type
- 14.11.2. By Drug Class
- 14.11.3. By Indication
- 14.11.4. By Distribution Channel
- 14.11.5. By Country/Sub-region

15. Middle East & Africa Sterile Injectable Drugs Market ;Analysis and Forecast

15.1. Introduction
- 15.1.1. Key Findings
15.2. Market Value Forecast, by Type, 2017-2031
- 15.2.1. Small Molecule
- 15.2.2. Large Molecule
15.3. Market Attractiveness, by Type
15.4. Market Value Forecast, by Drug Class, 2017-2031
- 15.4.1. Monoclonal Antibodies (Mabs)
- 15.4.2. Cytokines
- 15.4.3. Insulin
- 15.4.4. Peptide Hormones
- 15.4.5. Vaccine
- 15.4.6. Immunoglobulins
- 15.4.7. Blood Factors
- 15.4.8. Peptide Antibiotics
- 15.4.9. Others
15.5. Market Attractiveness, by Drug Class
15.6. Market Value Forecast, by Indication, 2017-2031
- 15.6.1. Cardiology & Metabolic Disorders
- 15.6.2. Neurology
- 15.6.3. Oncology
- 15.6.4. Autoimmune
- 15.6.5. Gastroenterology
- 15.6.6. Hematology
- 15.6.7. Pain
- 15.6.8. Infectious Disease
- 15.6.9. Others
15.7. Market Attractiveness, by Indication
15.8. Market Value Forecast, by Distribution Channel, 2017-2031
- 15.8.1. Hospital Pharmacy
- 15.8.2. Retail Pharmacy
- 15.8.3. E-commerce
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by Country/Sub-region, 2017-2031
- 15.10.1. GCC Countries
- 15.10.2. South Africa
- 15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
- 15.11.1. By Type
- 15.11.2. By Drug Class
- 15.11.3. By Indication
- 15.11.4. By Distribution Channel
- 15.11.5. By Country/Sub-region

16. Competition Landscape

16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
- 16.3.1. Baxter International
  - 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.1.2. Type Portfolio
  - 16.3.1.3. Financial Overview
  - 16.3.1.4. SWOT Analysis
  - 16.3.1.5. Strategic Overview
- 16.3.2. Sanofi S.A
  - 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.2.2. Type Portfolio
  - 16.3.2.3. Financial Overview
  - 16.3.2.4. SWOT Analysis
  - 16.3.2.5. Strategic Overview
- 16.3.3. Pfizer, Inc.
  - 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.3.2. Type Portfolio
  - 16.3.3.3. Financial Overview
  - 16.3.3.4. SWOT Analysis
  - 16.3.3.5. Strategic Overview
- 16.3.4. GlaxoSmithKline Plc.
  - 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.4.2. Type Portfolio
  - 16.3.4.3. Financial Overview
  - 16.3.4.4. SWOT Analysis
  - 16.3.4.5. Strategic Overview
- 16.3.5. AstraZeneca
  - 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.5.2. Type Portfolio
  - 16.3.5.3. Financial Overview
  - 16.3.5.4. SWOT Analysis
  - 16.3.5.5. Strategic Overview
- 16.3.6. Merck & Co., Inc.
  - 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.6.2. Type Portfolio
  - 16.3.6.3. Financial Overview
  - 16.3.6.4. SWOT Analysis
  - 16.3.6.5. Strategic Overview
- 16.3.7. Novartis AG
  - 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.7.2. Type Portfolio
  - 16.3.7.3. Financial Overview
  - 16.3.7.4. SWOT Analysis
  - 16.3.7.5. Strategic Overview
- 16.3.8. Johnson & Johnson Services, Inc.
  - 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.8.2. Type Portfolio
  - 16.3.8.3. Financial Overview
  - 16.3.8.4. SWOT Analysis
  - 16.3.8.5. Strategic Overview
- 16.3.9. Novo Nordisk A/S
  - 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.9.2. Type Portfolio
  - 16.3.9.3. Financial Overview
  - 16.3.9.4. SWOT Analysis
  - 16.3.9.5. Strategic Overview
- 16.3.10. Gilead Sciences, Inc.
  - 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.10.2. Type Portfolio
  - 16.3.10.3. Financial Overview
  - 16.3.10.4. SWOT Analysis
  - 16.3.10.5. Strategic Overview

한글목차

무균 주사제 시장 - 보고서 범위

목차

제1장 서문

제2장 가정과 조사 방법

제3장 주요 요약 : 세계 시장

제4장 시장 개요

제5장 중요한 인사이트

제6장 세계 시장 분석과 예측 : 유형별

제7장 세계 시장 분석과 예측 : 약제 클래스별

제8장 세계 시장 분석과 예측 : 적응증별

제9장 세계 시장 분석과 예측 : 유통 채널별

제10장 세계 시장 분석과 예측 : 지역별

제11장 북미 시장 분석과 예측

제12장 유럽 시장 분석과 예측

제13장 아시아태평양 시장 분석과 예측

제14장 라틴아메리카 시장 분석과 예측

제15장 중동 및 아프리카 시장 분석과 예측